longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Vertex Pharma

VRTX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfileWeekly ReviewWeekly Review
LongbridgeAI

Current ValuationThe current P/E ratio is 29.61, within the reasonable range, cheaper than 46.74% of the time in the past 1 years, and the industry ranks 47/601, the industry Median -2.44.

29.61xP/E
$514.63Stock price
$17.38Earnings per share
29.61xP/E
Stock price$514.63Earnings per share$17.38

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
29.38x
Typical range
27.65x–31.32x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
AMGNUSAmgen
23.23x11.10%$203.09B
VRTXUSVertex Pharma
29.61x36.49%$130.44B
REGNUSRegeneron Pharma
18.41x4.10%$79.70B
INCYUSIncyte
15.30x65.04%$24.68B
UTHRUSUnited Therap
16.37x6.53%$21.46B
GMABUSGenmab A/S
26.65x24.93%$21.00B
ASNDUSAscendis Pharmac
18.32x479.53%$15.77B
NBIXUSNeurocrine Biosciences
21.62x50.66%$15.25B
EXELUSExelixis
16.38x16.46%$14.10B
HALOUSHalozyme Therap
29.16x181.51%$12.06B
TGTXUSTG Therap
18.39x65.83%$8.12B
VCYTUSVeracyte
28.19x35.02%$3.23B
CDNAUSCaredex
24.53x629.58%$2.72B
MGTXUSMeiraGTx
15.52x122.03%$1.23B
PBYIUSPuma BioTech
17.87x37.70%$477.49M
KMDAUSKamada
20.98x39.29%$466.88M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.